Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAF^V600-mutant advanced melanoma: a multicenter cohort study.

ABSTRACT: Anti-PD-1 immunotherapy and targeted therapy (TT) represent two major therapeutic modalities for BRAF^V600-mutant advanced melanoma, but the efficacy of combination therapy in Asian populations remains unknown. Asian melanoma patients differ significantly from Caucasians in tissue subtypes, pathogenesis and response to treatment. We retrospectively analyzed data of BRAF^V600-mutant advanced melanoma patients treated with first-line vemurafenib (V) ± anti-PD-1 or dabrafenib+trametinib (D+T) ± anti-PD-1 between 2014 and 2023 from three centers in China. 178 patients were included, with V (n = 45), D+T (n = 51), V+anti-PD-1 (n = 39) and D+T+anti-PD-1 (n = 43). The median PFS (21.9 vs. 11.1 months, p < 0.001), OS (NR vs. 32.6 months, p<

SUBMITTER: Wu J 

PROVIDER: S-EPMC11832434 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature